Molecular classification of prostate cancer using curated expression signatures

High Gleason score is currently the best prognostic indicator for poor prognosis in prostate cancer. However, a significant number of patients with low Gleason scores develop aggressive disease as well. In an effort to understand molecular signatures associated with poor outcome in prostate cancer, we analyzed a microarray dataset characterizing 281 prostate cancers from a Swedish watchful-waiting cohort. Patients were classified on the basis of their mRNA microarray signature profiles indicating embryonic stem cell expression patterns (stemness), inactivation of the tumor suppressors p53 and PTEN, activation of several oncogenic pathways, and the TMPRSS2–ERG fusion. Unsupervised clustering identified a subset of tumors manifesting stem-like signatures together with p53 and PTEN inactivation, which had very poor survival outcome, a second group with intermediate survival outcome, characterized by the TMPRSS2–ERG fusion, and three groups with benign outcome. The stratification was validated on a second independent dataset of 150 tumor and metastatic samples from a clinical cohort at Memorial Sloan–Kettering Cancer Center. This classification is independent of Gleason score and therefore provides useful unique molecular profiles for prostate cancer prognosis, helping to predict poor outcome in patients with low or average Gleason scores.

[1]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[4]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Perou,et al.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.

[6]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[7]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[9]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[10]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[11]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[12]  S. Serrano,et al.  KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.

[13]  J. Cuzick,et al.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.

[14]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[15]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[16]  M. Loda,et al.  Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.

[17]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[18]  Manuel Serrano,et al.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.

[19]  M. Blasco,et al.  The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.

[20]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[21]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[22]  Jeroen S. van Zon,et al.  Direct cell reprogramming is a stochastic process amenable to acceleration , 2009, Nature.

[23]  M. Gerstein,et al.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.

[24]  W. Isaacs,et al.  TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.

[25]  D. Berney,et al.  Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer , 2009 .

[26]  A. Levine,et al.  Stem cell biology meets p53 , 2009, Nature Biotechnology.

[27]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[28]  R. Kittles,et al.  Association of CD14 variant with prostate cancer in African American men , 2010, The Prostate.

[29]  Jaya M Satagopan,et al.  TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features , 2010, Modern Pathology.

[30]  G. Wahl,et al.  Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures , 2010, Proceedings of the National Academy of Sciences.

[31]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[32]  Sebastián M. Real,et al.  E2F1 Regulates Cellular Growth by mTORC1 Signaling , 2011, PloS one.

[33]  S. Kwon,et al.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[34]  Chris Sander,et al.  MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors , 2011, PloS one.

[35]  S. Abdulkadir,et al.  A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53 , 2011, Oncogene.